Connect with us


LEO Pharma Grows 6.9% in 2023 and Has a Turnover of 93.2 Million Euros

LEO Pharma, specializing in medical dermatology and thrombosis, saw a 7% revenue increase in 2023, reaching €1.54 billion in net sales. In Spain, growth was 6.9%, totaling €93.2 million. Key products include Tralokinumab and Protopic, with significant growth in the thrombosis treatment area. The company remains committed to innovative biological treatments.



leo pharma

LEO Pharma grows. The Danish pharmaceutical laboratory specialized in medical dermatology and thrombosis closed the last year registering a growth of 7% in its income compared to the previous year, thus reaching 1.53 billion euros in net sales. In Spain, the company’s growth was 6.9%, which translates into 93.2 million euros.

The general director of LEO Pharma Iberia, Juan Fran Cuello de Oro, has detailed that “ these economic results confirm the growth of our company in different business areas, consolidating our commitment to biological treatments and establishing ourselves in the sector.”

The company has issued a statement to make the news public, and has taken the opportunity to highlight the importance of medical dermatology . “Skin pathologies can be very serious and have a significant impact on patients’ quality of life.” He added that, “in Spain, the dermatology business unit achieved a total of 59.4 million euros.”

The Danish company has reached 1.54 billion euros in net sales in 2023

Tralokinumab (Adtralza), a biologic for moderate to severe atopic dermatitis, stands out among other products for its 2023 sales , which reached 7.6 million euros. The topical Protopic, also to treat atopic dermatitis, has grown by 18% and Enstilar is the most consolidated product in terms of turnover, representing 22% of total sales. For its part, the business area dedicated to the treatment of thrombosis has also grown significantly, up to 20% compared to the previous year.

Currently, LEO Pharma is the only laboratory specialized in medical dermatology that covers the entire spectrum of severity of two diseases such as atopic dermatitis and psoriasis , which are highly prevalent.

LEO Pharma is a company founded in Denmark in 1908, owned by the LEO Foundation, one of the largest Danish commercial foundations, with assets of around €2 billion, and the Nordic Capital fund. In 2022, this company obtained a worldwide turnover of 1.43 billion euros.

LEO Pharma Iberia added Isabel Betoret to its team

LEO Pharma renews its board of directors. The pharmaceutical company, dedicated to developing medications for thrombosis and dermatological solutions, has appointed Isabel Betoret as director of market access and corporate affairs for its subsidiary in Iberia .

Betoret joins to lead both in Spain and Portugal the market access strategies in the different business lines of the laboratory and the strategic area of ​​corporate affairs. In this way, he joins as a member of Iberia’s leadership team.

“I face this new challenge at LEO Pharma with the greatest of enthusiasm and with the aim of contributing to the achievement of business objectives, the development of people and the consolidation of LEO Pharma as a key agent in the Iberian healthcare system” , explains Betoret.

LEO Pharma bets on Bertoret, who has previously worked at Gebro Pharma and Novartis

Previously, Betoret has worked at the Gebro Pharma laboratory as market access and KAM head. She has also held positions of responsibility at Novartis, both in the Marketing, Access and Sales areas, leading drug launches in different therapeutic areas.

Isabel has a degree in Pharmacy and has an Executive MBA from Esade , as well as postgraduate training in areas such as market access and pharmaceutical marketing. Through her professional career in companies in the pharmaceutical sector, the company points out that “Isabel Betoret stands out for her initiative, business orientation and communication skills.”


(Featured image by Raimond Klavins via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce and PlantaDoce A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.